Study: Kidney Disease Tied to Increase Risk of C. Diff Death

Researchers at the Alfred Einstein School of Medicine's Jacobi Medical Center have found that C. diff is especially deadly for people who have end-stage renal disease (ESRD).

The researchers also found that combining metronidazole and oral or rectal vancomycin was more effective than monotherapy drug treatment for the ESRD patients with C. diff. ESRD patients were also more likely to have a relapse of C. diff infection within two months. An increased risk of relapse was seen with monotherapy drug treatment. 

To learn more, click here.